Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Beam Therapeutics Inc. Common Stock (BEAM)

Biological Products, (no Disgnostic Substances)

https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

26 LANDSDOWNE STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/06/2020

Market Cap

2,027,423,760

Shares Outstanding

81,500,000

Weighted SO

81,504,057

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

EDIT --.--%

CRSP --.--%

CRBU --.--%

VERV --.--%

NTLA --.--%

FATE --.--%

PRME --.--%

VRTX --.--%

DNA --.--%

Beta

1.8660

Last Div

0.0000

Range

16.95-49.5

Chg

-0.2600

Avg Vol

1282948

Mkt Cap

2027423760

Exch

NASDAQ

Country

US

Phone

857 327 8775

DCF Diff

38.8986

DCF

-0.4785

Div Yield

0.0000

P/S

5.7505

EV Multiple

-11.3394

P/FV

2.3708

Div Yield %

0.0000

P/E

-14.1590

PEG

-0.2610

Payout

0.0000

Current Ratio

5.8051

Quick Ratio

5.8051

Cash Ratio

1.6509

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

67.7984

CCC

-67.7984

Gross Margin

0.9324

Op Margin

-0.5231

Pretax Margin

-0.4016

Net Margin

-0.4056

Eff Tax Rate

0.0747

ROA

-0.1134

ROE

-0.1622

ROCE

-0.1702

NI/EBT

1.0099

EBT/EBIT

0.7678

EBIT/Rev

-0.5231

Debt Ratio

0.1310

D/E

0.1935

LT Debt/Cap

0.1516

Total Debt/Cap

0.1621

Int Coverage

-4.7350

CF/Debt

-0.8319

Equity Multi

1.4767

Rec Turnover

0.0000

Pay Turnover

5.3836

Inv Turnover

0.0000

FA Turnover

1.5715

Asset Turnover

0.2795

OCF/Share

-1.6701

FCF/Share

-1.8637

Cash/Share

12.2480

OCF/Sales

-0.3899

FCF/OCF

1.1159

CF Coverage

-0.8319

ST Coverage

-10.8747

CapEx Coverage

-8.6262

Div&CapEx Cov

-8.6262

P/BV

2.3708

P/B

2.3708

P/S

5.7505

P/E

-14.1590

P/FCF

-13.2163

P/OCF

-14.7300

P/CF

-14.7300

PEG

-0.2610

P/S

5.7505

EV Multiple

-11.3394

P/FV

2.3708

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 08, 18:45 Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting GlobeNewswire Inc. Dec 07, 16:30 Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Benzinga Jul 19, 02:12 Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast - Benzinga GlobeNewswire Inc. Jan 08, 06:30 Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones The Motley Fool Jan 08, 05:52 4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 GlobeNewswire Inc. Jan 02, 06:30 Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference The Motley Fool Dec 27, 10:30 2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street The Motley Fool Dec 27, 10:30 2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street GlobeNewswire Inc. Dec 14, 06:30 Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors Benzinga Dec 08, 07:20 Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday The Motley Fool Dec 04, 08:30 You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. Benzinga Nov 29, 13:32 Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception The Motley Fool Nov 18, 07:15 Is Beam Therapeutics Stock a Buy Now? The Motley Fool Nov 18, 07:15 Is Beam Therapeutics Stock a Buy Now? The Motley Fool Nov 18, 06:49 3 Monster Stocks in the Making The Motley Fool Nov 18, 06:49 3 Monster Stocks in the Making The Motley Fool Nov 14, 05:50 Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks MarketWatch Nov 13, 09:01 Verve Therapeutics stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment GlobeNewswire Inc. Nov 08, 06:30 Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference The Motley Fool Nov 05, 08:30 2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.22 02/04/2014 01/23/2014 02/06/2014 03/03/2014
0.22 11/04/2013 09/20/2013 11/06/2013 12/02/2013
0.22 08/12/2013 07/31/2013 08/14/2013 09/03/2013
0.22 05/06/2013 04/24/2013 05/08/2013 06/03/2013
0.22 02/04/2013 01/25/2013 02/06/2013 03/01/2013
0.21 11/05/2012 10/04/2012 11/30/-0001 12/03/2012
0.21 08/06/2012 07/24/2012 11/30/-0001 09/04/2012
0.21 05/07/2012 04/26/2012 11/30/-0001 06/01/2012
0.21 02/06/2012 01/30/2012 11/30/-0001 03/01/2012
0.19 11/07/2011 11/30/-0001 11/30/-0001 12/01/2011